Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Coronary Artery Disease, Heart Disease, Cardiac Disease
- Main trialPhase 4
- “The study is designed to see if stress echocardiography can be used as a screening exam in peri-, or post-menopausal women with a risk of developing of coronary artery disease and experiencing future cardiac events.”In the company’s words, NCT00162370 on ClinicalTrials.gov
Other drugs for Coronary Artery Disease
- XTR004Sinotau Pharmaceutical Group · Phase 3
- EA-230EBI Anti Sepsis BV · Phase 3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
- ZiltivekimabNovo Nordisk · Phase 3
- RetatrutideEli Lilly · Phase 3
Copies tested against it1
Other companies’ versions, mostly cheaper copies for when the patent ends
- MVT-100Microvascular Therapeutics, LLC · NCT03882359 · finished
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | Sep 2012 | A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease | |
| Phase 3Completed | 9 Jan 2020 | DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026